“I would like to extend a warm thank you to all of our speakers and guests who helped make our inaugural analyst and investor event a fantastic success last week. We were honoured to have had an all-star lineup of clinical presenters from the US, Canada and Europe share their experience with TULSA-PRO® and SONALLEVE®, as well as their vision of the future of our technologies. The presentations were amazing as each presenter covered a different aspect of the value equation.
I believe most people on Wall Street know that the term “incision free surgery” is no longer an oxymoron. Profound’s Customizable, Predictable, Incision-free platforms take this concept to a whole new level. Imagine for a moment, a patient is diagnosed with prostate cancer in the morning, in the afternoon he is treated with TULSA-PRO® and in the same evening he can be home at the dinner table. This patient can then tell his family of not only the diagnosis, but that the disease has already been treated. This family can then go on to plan a fun weekend just as though the diagnosis and treatment had not even occurred. This is no longer just a vision of tomorrow; this is the reality of today.
Our TULSA-PRO® and SONALLEVE® technologies have a lot to offer to all stakeholders. I strongly believe that we can generate significant value for our investors with a compelling recurring revenue business model that has already been validated in Europe.
All of us at Profound are proud and excited to be advancing new technologies that have a truly profound impact on patients’ lives and on the future of healthcare.”
Arun Menawat, CEO
Profound Medical